Skip to content
You are now leaving to visit

Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile BOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,